Gabelli Funds LLC Bluebird Bio, Inc. Transaction History

Gabelli Funds LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	SELL	$1.32 - $4.83 $3,960 - $14,490	-3,000 Reduced 23.08%	10,000 $13,000
Q3 2023 Nov 08, 2023	SELL	$3.02 - $4.05 $9,060 - $12,150	-3,000 Reduced 18.75%	13,000 $39,000
Q1 2023 May 12, 2023	SELL	$3.14 - $8.22 $12,560 - $32,880	-4,000 Reduced 20.0%	16,000 $50,000
Q4 2022 Feb 13, 2023	SELL	$5.77 - $8.49 $34,620 - $50,940	-6,000 Reduced 23.08%	20,000 $138,000
Q2 2022 Aug 12, 2022	SELL	$2.94 - $5.23 $44,100 - $78,450	-15,000 Reduced 36.59%	26,000 $108,000
Q4 2021 Feb 11, 2022	SELL	$8.96 - $16.31 $11,047 - $20,110	-1,233 Reduced 2.92%	41,000 $410,000
Q3 2021 Nov 12, 2021	SELL	$11.24 - $21.0 $146,120 - $273,000	-13,000 Reduced 23.54%	42,233 $807,000
Q1 2021 May 14, 2021	BUY	$16.59 - $33.89 $916,315 - $1.87 Million	55,233 New	55,233 $1.67 Million

128

62.8M

264K

428K

Ticker BLUE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,121,800
Market Cap $598M
Description
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell ...

Get notified when there are updates to the investment portfolio of Gabelli Funds LLC, based on Form 13F filings with the SEC.

Stay updated on Gabelli Funds LLC with notifications on news.